153 related articles for article (PubMed ID: 38455035)
1. The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A.
Oomen I; Verhagen M; Miranda M; Allacher P; Beckers EAM; Blijlevens NMA; van der Bom JG; Coppens M; Driessens M; Eikenboom JCJ; Fijnvandraat K; Hassan S; van Heerde WL; Hooimeijer HL; Jansen JH; Kaijen P; Leebeek FWG; Meijer D; Paul H; Rijpma SR; Rosendaal FR; Smit C; van Vulpen LFD; Voorberg J; Schols SEM; Gouw SC
Front Immunol; 2024; 15():1355813. PubMed ID: 38455035
[TBL] [Abstract][Full Text] [Related]
2. The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A.
Valke LLFG; Verhagen MJA; Mulders BTPM; Polenewen R; Blijlevens NMA; Jansen JH; Mansouritorghabeh H; Elsheikh E; Reipert BM; Turecek PL; O'Donnell JS; Rijpma SR; Schols SEM; van Heerde WL; Meijer D
Thromb Res; 2023 Nov; 231():112-120. PubMed ID: 37844518
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive domain-specific analysis and immunoglobulin G profiling of anti-factor VIII antibodies using a bead-based multiplex immunoassay.
Pezeshkpoor B; Berkemeier AC; Herbst K; Albert T; Müller J; Oldenburg J
J Thromb Haemost; 2024 Jun; 22(6):1591-1604. PubMed ID: 38453023
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.
Boylan B; Rice AS; Dunn AL; Tarantino MD; Brettler DB; Barrett JC; Miller CH; ;
J Thromb Haemost; 2015 Jan; 13(1):47-53. PubMed ID: 25354263
[TBL] [Abstract][Full Text] [Related]
6. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients.
Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
Haemophilia; 2015 Sep; 21(5):686-92. PubMed ID: 25708525
[TBL] [Abstract][Full Text] [Related]
7. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.
Whelan SF; Hofbauer CJ; Horling FM; Allacher P; Wolfsegger MJ; Oldenburg J; Male C; Windyga J; Tiede A; Schwarz HP; Scheiflinger F; Reipert BM
Blood; 2013 Feb; 121(6):1039-48. PubMed ID: 23243272
[TBL] [Abstract][Full Text] [Related]
8. Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.
Miller CH; Boylan B; Shapiro AD; Lentz SR; Wicklund BM;
J Thromb Haemost; 2017 Oct; 15(10):1971-1976. PubMed ID: 28795528
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of anti-factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents.
Boylan B; Niemeyer GP; Werner B; Miller CH
Haemophilia; 2021 Jan; 27(1):e40-e50. PubMed ID: 33216433
[TBL] [Abstract][Full Text] [Related]
10. Two-center validation of assays for the detection of binding and neutralizing anti-factor VIII antibodies.
Müller J; Neimanis S; Kahle J; Albert T; Schultze Strasser S; Rup B; Pötzsch B; Königs C; Oldenburg J;
Haemophilia; 2024 Jan; 30(1):224-231. PubMed ID: 37824540
[TBL] [Abstract][Full Text] [Related]
11. FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors.
Hofbauer CJ; Kepa S; Schemper M; Quehenberger P; Reitter-Pfoertner S; Mannhalter C; Reipert BM; Pabinger I
Blood; 2016 Jul; 128(2):293-6. PubMed ID: 27216215
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.
Batlle J; Gómez E; Rendal E; Torea J; Lourés E; Couselo M; Vila P; Sedano C; Tusell X; Magallón M; Quintana M; González-Boullosa R; López-Fernández MF
Ann Hematol; 1996 May; 72(5):321-6. PubMed ID: 8645745
[TBL] [Abstract][Full Text] [Related]
13. Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients.
Rampersad AG; Boylan B; Miller CH; Shapiro A
Haemophilia; 2018 Sep; 24(5):807-814. PubMed ID: 30004159
[TBL] [Abstract][Full Text] [Related]
14. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity.
Towfighi F; Gharagozlou S; Sharifian RA; Kazemnejad A; Esmailzadeh K; Managhchi MR; Shokri F
Acta Haematol; 2005; 114(2):84-90. PubMed ID: 16103630
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal profiling of anti-factor VIII antibodies in Japanese patients with congenital hemophilia A during factor VIII replacement and immune-tolerance induction therapy.
Yoshimura T; Furukawa S; Oda A; Matsumoto T; Sasai K; Shima M; Nogami K
Int J Hematol; 2022 Sep; 116(3):423-433. PubMed ID: 35503593
[TBL] [Abstract][Full Text] [Related]
16. Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII.
Pezeshkpoor B; Sereda N; Berkemeier AC; Matuschek I; Schwarz N; Turecek PL; Horneff S; Klein C; Goldmann G; Marquardt N; Albert T; Müller J; Oldenburg J
J Thromb Haemost; 2023 Jun; 21(6):1503-1514. PubMed ID: 36934798
[TBL] [Abstract][Full Text] [Related]
17. The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development.
Reipert BM; Gangadharan B; Hofbauer CJ; Berg V; Schweiger H; Bowen J; Blatny J; Fijnvandraat K; Mullins ES; Klintman J; Male C; McGuinn C; Meeks SL; Radulescu VC; Ragni MV; Recht M; Shapiro AD; Staber JM; Yaish HM; Santagostino E; Brown DL
Blood Adv; 2020 Nov; 4(22):5785-5796. PubMed ID: 33232473
[TBL] [Abstract][Full Text] [Related]
18. Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.
Boylan B; Rice AS; Neff AT; Manco-Johnson MJ; Kempton CL; Miller CH;
J Thromb Haemost; 2016 Oct; 14(10):1931-1940. PubMed ID: 27501440
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.
Miller CH; Rice AS; Boylan B; Shapiro AD; Lentz SR; Wicklund BM; Kelly FM; Soucie JM;
J Thromb Haemost; 2013 Jul; 11(7):1300-9. PubMed ID: 23601690
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services.
Oudat R; Al-Maharmeh M; Al-Ghrayeb R; Ogeilat T; Mustafa MK
Med Arch; 2020 Jun; 74(3):187-190. PubMed ID: 32801433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
